Počet záznamů: 1
SGIP1 in axons prevents internalization of desensitized CB1R and modifies its function
- 1.
SYSNO ASEP 0575884 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název SGIP1 in axons prevents internalization of desensitized CB1R and modifies its function Tvůrce(i) Durydivka, Oleh (UMG-J)
Mackie, K. (US)
Blahoš, Jaroslav (UMG-J) RIDCelkový počet autorů 3 Číslo článku 1213094 Zdroj.dok. Frontiers in Neuroscience
Roč. 17, Jul (2023)Poč.str. 11 s. Jazyk dok. eng - angličtina Země vyd. CH - Švýcarsko Klíč. slova cannabinoid receptor 1 ; synaptic transmission ; axon enrichment ; clathrin-mediated endocytosis ; internalization Obor OECD Biochemistry and molecular biology CEP GA19-24172S GA ČR - Grantová agentura ČR GA21-02371S GA ČR - Grantová agentura ČR Způsob publikování Open access Institucionální podpora UMG-J - RVO:68378050 UT WOS 001039801200001 EID SCOPUS 85166532925 DOI 10.3389/fnins.2023.1213094 Anotace In the central nervous system (CNS), cannabinoid receptor 1 (CB1R) is preferentially expressed in axons where it has a unique property, namely resistance to agonist-driven endocytosis. This review aims to summarize what we know about molecular mechanisms of CB1R cell surface stability in axonal compartments, how these impact CB1R signaling, and to consider their physiological consequences. This review then focuses on a potential candidate for maintaining axonal CB1R at the cell surface, Src homology 3-domain growth factor receptor-bound 2-like endophilin interacting protein 1 (SGIP1). SGIP1 may contribute to the polarized distribution of CB1R and modify its signaling in axons. In addition, deletion of SGIP1 results in discrete behavioral changes in modalities controlled by the endocannabinoid system in vivo. Several drugs acting directly via CB1R have important therapeutic potential, however their adverse effects limit their clinical use. Future studies might reveal chemical approaches to target the SGIP1-CB1R interaction, with the aim to exploit the endocannabinoid system pharmaceutically in a discrete way, with minimized undesired consequences. Pracoviště Ústav molekulární genetiky Kontakt Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Rok sběru 2024 Elektronická adresa https://www.frontiersin.org/articles/10.3389/fnins.2023.1213094/full
Počet záznamů: 1